CHO PHARMA INC has a total of 24 patent applications. It decreased the IP activity by 95.0%. Its first patent ever was published in 2017. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are PALLEON PHARMACEUTICALS INC, GAMAMABS PHARMA and MABVAX THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | China | 3 | |
#4 | EPO (European Patent Office) | 3 | |
#5 | Taiwan | 3 | |
#6 | Canada | 2 | |
#7 | Republic of Korea | 2 | |
#8 | Australia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Enzymes | |
#5 | Microorganisms | |
#6 | Analysing materials | |
#7 | Fermentation |
# | Name | Total Patents |
---|---|---|
#1 | Lin Nan-Horng | 16 |
#2 | Wong Chi-Huey | 11 |
#3 | Chu Kuo-Ching | 8 |
#4 | Cheng Ting | 8 |
#5 | Huang Lin-Ya | 7 |
#6 | Shivatare Sachin S | 7 |
#7 | Wong Chi Huey | 6 |
#8 | Chen Chien-Yu | 6 |
#9 | Lin Nan Horng | 6 |
#10 | Wu Han-Chung | 6 |
Publication | Filing date | Title |
---|---|---|
WO2021026264A1 | Fusion protein for remodeling antibody glycoform | |
CN109996543A | Antibody drug complex | |
US2018291109A1 | Antibodies, binding fragments, and methods of use |